Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Treatment options for patients with triple-negative breast cancer | Santana-Davila and Perez Journal of Hematology Oncology 2010 3 42 http www.jhoonline.Org content 3 1 42 JOURNAL OF HEMATOLOGY ONCOLOGY REVIEW Open Access Treatment options for patients with triple-negative breast cancer Rafael Santana-Davila1 Edith A Perez2 Abstract Breast cancer is a heterogeneous disease composed of different subtypes characterized by their different clinico-pathological characteristics prognoses and responses to treatment. In the past decade significant advances have been made in the treatment of breast cancer sensitive to hormonal treatments as well as in patients whose malignant cells overexpress or amplify HER2. In contrast mainly due to the lack of molecular targets little progress has been made in the treatment of patients with triple-negative breast cancer. Recent improved understanding of the natural history pathophysiology and molecular features of triple-negative breast cancers have provided new insights into management and therapeutic strategies for women affected with this entity. Ongoing and planned translational clinical trials are likely to optimize and improve treatment of women with this disease. Introduction Breast cancer affected an estimated 192 370 women and men in 2009 and was responsible for 40 170 deaths during the same year 1 . It is now clear that it is a disease composed of multiple subgroups characterized by their pathophysiological features outcomes and responses to treatment. The heterogeneity of this disease underscores the need for treatments to be tailored for a specific patient depending on the molecular characteristics of their malignancy. An initial subdivision of patients with breast cancer can be done by immunohistochemical techniques separating those whose malignant cells express either estrogen ER or progesterone receptors PgR and those that do not as the first two can be treated with endocrine therapy. Immunohistochemistry IHC or fluorescence in situ hybridization FISH can also detect the overexpression or
